Insights

Legal considerations and practical tips for businesses in the pharmaceuticals and life sciences sector.

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it is developing a new strategy to provide its direction, mission, values and focus through to 2030. What should we expect?

It's been a challenging few weeks for the UK life sciences sector. Following the breakdown of the talks with the Government to provide a more competitive reimbursement scheme for pharma, there have been a number of high-profile decisions that have created big concerns for the future of the sector. However, there have been some good news stories too, including a resilient message from MedCity - the life sciences arm of London and Partners, with whom VWV is a partner.

VWV are delighted to have acted for the sellers of Renascience Pharma in the sale of the company to pharmaceutical major Lupin, through its UK subsidiary.

Medicine shortages are an important issue in the UK, with significant implications for patients and healthcare professionals, as well as suppliers and distributors, and the wider health system. 

Following the Government's publication of the 10 year Industrial Strategy, it has now published its sector plans for its eight growth sectors (the IS-8) - one of which being the Life Sciences Sector Plan. But what does it say?